Cost Minimization Analysis of Insulin Glargine 300 U/Ml Vs Glargine 100 U/Ml for the Management of Type 2 Diabetes from A Private and Public Third-Party Payer Perspective in Chile
Abstract
Authors
M Russo R Bitran JC Rodriguez B Grassi P Aguilera